First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting

06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program Related Posts Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS 23 December 2019 Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood 9 December 2019 Webcast on masitinib in severe asthma on Monday, December 2, 2019 26 November 2019 Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis 25 November 2019 Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities 22 November 2019 Positive top-line Phase 3 results for masitinib in severe asthma 7 November 2019 Search Recent Posts AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026 AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development AB Science announces the successful completion of a EUR 2.3 million private placement AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML AB SCIENCE HEADQUARTER 3, Avenue George V – 75008 PARIS – FRANCE Tel. : +33 (0)1 47 20 00 14 Fax. : +33 (0)1 47 20 24 11 GENERAL INQUIRIES [email protected] PRODUCT INQUIRIES [email protected] JOB INQUIRIES [email protected] CLINICAL INQUIRIES [email protected] MEDIA / FINANCIAL INQUIRIES [email protected] PHARMACOVIGILANCE [email protected] Fax : +33 1 47 20 10 82

The release as fetched from its publisher. ab-science.com ↗